Europe Gout Therapeutics Market

Europe Gout Therapeutics Market

Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals, in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis, joint damage, tophi formation, and urate nephropathy. The gout therapeutics market in the European countries is likely to expand at a rapid pace during the forecast period. UK and Germany are projected to retain its share of the gout therapeutics market during the forecast period 2022 to 2029. Moreover, high incidence of gout arthritis is anticipated to propel the market in the European region over the forecast period.

Promising drug pipeline and approvals to propel gout therapeutics market

Numerous pipeline products and recent approvals of drugs to treat gout therapeutics are expected to the new opportunity for the market. For instance, in December 2021, Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1/2 study of ALN-XDH, an investigational RNAi therapeutic targeting xanthine dehydrogenase (XDH) for the treatment of gout. 

Growing burden of gout therapeutics with the increasing geriatric population

The major factors that fuel the growth of the market are the growing burden of gout therapeutics with the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, larger cases of this disease can be found in aged population reaching hospitals. A retrospective analysis of patients with gout, identified through the records of 2.5 million patients in UK. The prevalence of gout was 1.4% in the UK and Germany. Obesity was the most common comorbidity in the UK (27.7%), but in Germany the most common comorbidity was diabetes (25.9%).

Several epidemiologic studies have shown that gout is the most common inflammatory arthritis in men in France among men ages 35–39 years and 2.0% among men 40–44 years. Gout therefore appears to be the most frequent inflammatory arthritis in French adults, with a prevalence approximately 3-fold higher than that for rheumatoid arthritis.

The gout therapeutics market in the France is likely to expand at a rapid pace during the forecast period. The country is projected to retain its share of the gout therapeutics market from 2022 to 2029. Moreover, high incidence of gout arthritis is anticipated to propel the market in the France during the forecast period.

With the growing number of gout cases, the use of NSAIDs and their production is expected to observe healthy demand and supply throughout the forecast period.

Antihyperuricemic agents (urate-lowering drugs) is a growing segment in Gout Treatment Market

As per the research analysis, the gout therapeutics market is segmented by drug class into non-steroidal anti-inflammatory drugs (NSAIDs), anti-hyperuricemic agents (urate-lowering drugs), corticosteroids, colchicine, and others. Among these, urate lowering agents segment is expected to observe a growth rate of 6.5% during the forecast period. This is attributed to recently introduction of novel drugs, investment by several industry players for the development of urate lowering agents, and expected launch of anti-gout drugs during the forecast period.

Urate-lowering agents majorly consist of xanthine oxidase inhibitor and uricosuric agents. Growing adoption of this treatment and introduction of several drugs are likely to drive the industry during the forecast period.

Some of the most common drugs used in this segment are xanthine oxidase inhibitors (allopurinol and febuxostat), uricosuric medications (benzbromarone, probenecid, and sulfinpyrazone), and uricases (pegloticase and rasburicase).

DataM Intelligence - The Europe gout therapeutics market is expected to expand at a sluggish CAGR of 7% during the forecast period (2022-2029), and is estimated to surpass US$ 5,902.4 Mn by 2027. Demand for effective therapeutics for gout treatment is increasing. The gout therapeutics market in the UK and Germany is likely to expand at a rapid pace during the forecast period. These countries are projected to retain its share of the gout therapeutics market from 2022 to 2029. Moreover, high incidence of gout arthritis is anticipated to propel the market in the France during the forecast period. With the growing number of gout cases, the use of NSAIDs and their production is expected to observe healthy demand and supply throughout the forecast period.